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lion people yearly, and killing at least a
million. The intracellular protozoan para-
sites that cause the disease are endemic in
tropical areas and are spread by mosqui-
toes. In many areas, especially southeast
Asia, the parasite has become resistant to
existing antimalarials such as chloroquine.
Now with some help from western sci-
ence, an ancient Chinese herbal remedy
mayserve as the prototype for anewfamily
ofantimalarial drugs. At least three million
malaria patients have been treated with the
folk medicine, but it is far from a perfect
remedy. Western scientists hope to
improve the drug by changing its chemical
makeup. In 1972, Chinese scientists redis-
covered qinghaosu. This plant extract is
derived from the leaves ofArtemisia annua
a prolific shrub related to wormwood, and
has been used against fever for 2000 years.
The western name for the active compo-
nent is artemisinin. When the Chinese
found that it fought malaria, they put it
into clinical use. So far, the malaria para-
sites have shown no resistance to the sub-
stance, nor is artemisinin toxic at dinical
doses. And itworks quickly.
"It's very good for treating severe, life-
threatening malaria," says Steven R.
Meshnick, a parasitologist, biochemist, and
associate professor ofepidemiology at the
University ofMichigan School of Public
Health. Artemisinin revives comatose
patients much faster than quinine. But it's
not a cure. It's less useful in milder cases
and thedisas frequentlyreturns. Thedrug
is also poorly water soluble and difficult to
administer orally. And the body eiminates
itquickly, so itmustbetakenfrequently.
However, "Once you know exactly
where the drug works, and how, you can
then design it to work better," says
Meshnick. The essential part of the
artemisinin molecule is a peroxide bridge, a
chemical structure that's unusual and often
unstable. The molecule's selective toxicity is
due to the malaria parasite's diet ofhemo-
globin. The parasite digests the globin por-
tion but can't metabolize the iron-contain-
ing heme structure, which it stores in
hemozoin granules. The peroxide bridge
interactswith the iron andhemeexposed in
these granules to produce short-lived, high-
ly reactive free radicals. These free radicals
or related reactive intermediates damage
critical proteins in the parasite, killing it.
Thoughheme exists throughout thehuman
body, it's tucked inside proteins and thus
protectedfrom this reaction.
Artemisinin is a complex, multiringed
molecule, but all the rings aren't necessary
for the antimalarial effect. "We've tried to
simplifr the structure and arrive at com-
pounds that are equally potent and yet are
much easier to prepare in. the lab," says
Gary Posner, a medical chemist at Johns
Hopkins University. Posnerandothers have
used this mechanism-based design strategy
to synthesize hundreds of artemisinin
analogs, some ofwhich are as effectiVe as
artemisinin inanimalstudies.
Michael Bentley, chairperson of the
Department of Chemistry at the
University ofMaine, has employed a dif-
ferent tactic. Bendey attached artemisinin
to polymers ofpolyethylene glycol, a non-
toxic, nonallergenic compound used in
foods and drugs. Resulting compounds
tend to be soluble both in water and in
nonpolar solvents. Such structural modifi-
cations may lengthen artemisinin's stay in
the body. Plus, each polymer carries two
peroxide bridges. In studies with mice,
some of Bentley's compounds show
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gatherleavesofArtmisia annus,which contain a potential malaria treatmentdrug.
improved activity over artemisinin alone,
orchloroquine alone.
Artemisinin-based drugs are promising,
experts agree, but the coevolutionary arms
race with the malaria parasite will contin-
ue. Given the opportunity, the parasitewill
develop resistance. "Nothing is a cure-all,
magic bullet for all time," says Bentley.
Meshnick concurs, but notes that although
penicillin wasn't perfect either, it served as
a prototype for a whole new family of
antibiotics. "I really think the same thing
can happen forartemisinin," he says.
What's Causing Parkinson's?
The cause of Parkinson's disease has baf-
fled doctors ever since this chronic neuro-
logical syndrome was first described by
James Parkinson in 1817. Now scientists
may finally be closing in on the culprits.
The disease is likely to be caused by "some
admixture ofgenetic predisposition, aging,
and exposure to environmental toxicants,"
says Doyle Graham, chair ofthe pathology
department atVanderbilt UniversityMedi-
cal Center in Nashville.
Sorting out multiple potential causal
agents and the interactions among them
will never be easy. However, thanks to
increasingly sophisticated research tech-
niques, it may now be possible. A prime
example of the kind of meticulously
designed research needed for this purpose
is a case-control study currently being
completed at Henry Ford Health System
in Detroit. "This is one ofonly two popu-
lation-based studies to date in Parkinson's
epidemiology, and it's the only one of
which I'm aware in which an industrial
hygienist's assessment of exposures, based
ondetailed occupational histories, has been
used," saysJay M. Gorell, lead investigator
and director of the hospital's Parkinson's
disease center.
The study, now in the final data analy-
sis stage, induded 144 Parkinson's patients
and 469 control subjects who were
matched for age, race, and sex. Preliminary
analyses, based on all but 10 ofthe patients
and all but six of the controls, suggest an
increased risk ofParkinson's disease associ-
ated with exposure to manganese, copper,
and lead, as well as exposure to herbicides
and insecticides used at work. However, it
may take some combination of factors to
*produce Parkinson's disease. "It's possible
that an agent might act in a cumulative
wayovertime to partially disable acell, but
it might take several agents together to
cause the cell either to fail to finction or to
dieprematurely," says Gorell.
While some researchers are devoting
their energies to determining which envi-
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ronmental agents contribute to Parkinson's
disease, others are more concerned with
discovering how they do so. The spectrum
ofpossibilities ranges "from the enhanced
metabolism ofsubstances into their toxic
form to the diminished protection ofcells
from these kinds of toxic products," says
Graham. One hypothesis he is pursuing
relates to the potential role of transition
metals, such as manganese. Manganese
poisoning produces symptoms similar to
Parkinson's disease, although it affects a
different site in the brain. Graham and his
colleague, Thomas Montino, are currently
studying the effect oftransition metals on
neuroglial cells in tissue culture.
Graham and others believe that transi-
tion metals may contribute to the oxida-
tion of catecholamines, compounds that
carry signals between nerve cells. One way
that catecholamines are destroyed is by the
action of the enzyme monoamine oxidase
that results in the production ofhydrogen
peroxide, a known toxic compound.
Catecholamine oxidation can also occur by
metal-catalyzed processes that produce
their own toxic by-products. Of course,
cells have to cope with such natural toxins
on a regular basis, so they develop the abil-
ity to protect themselves from cellular
damage with enzymes that destroy toxins.
However, ifthe rate oftoxin production is
increased or the ability ofa cell to protect
itselfis lessened, this could lead to cellular
injuryover time.
As research presents new evidence for a
link between environmental agents and
Parkinson's disease, still other scientists are
trying to understand howsuch factors may
interact with a given individual's genetic
makeup. The most likely scenario seems to
be that a person can inherit a predisposi-
tion to develop the disease that is only later
activated by a toxic exposure. For example,
"a person may have a genetic defect in the
body machinery that deals with a toxic
compound, but ifthat person doesn't ever
come across this toxic agent, he may never
develop the disease," says Donato Di
Monte, director ofbiochemical toxicology
at the Parkinson's Institute in Sunnyvale,
California.
One major obstacle to all Parkinson's
research, however, is the lack ofan objec-
tive test to diagnose the condition. At pre-
sent, diagnosis is based on the clinical
assessment ofagiven patient's symptoms, a
method that can be inaccurate. The often
conflicting results of many older Park-
inson's studies may, in fact, be partly due
to a lack of standardization in diagnostic
criteria. Di Monte is among the scientists
now searching for biological markers of
Parkinson's disease, in the hopes of one
day developing a simple, reliable test for
the condition. Some ofhis work is aimed
at studying the products of oxidative
metabolism in spinal fluid.
The picture of Parkinson's remains
complicated. Says Di Monte, "We have to
start looking at the interactions between
environmental and genetic factors. And
among the environmental factors, we have
to start looking at interactions between
neurotoxins. Naturally, we would like to
have a simple experimental model, but
unfortunately that maynot be feasiblewith
Parkinson's disease."
2 ATION GRESS ALI
Stockholm, Sweden, September 15-20, 1996
The Congress will be a world-wide forum to share the latest scientific
advances within all principal fields of occupational safety and health.
The application of these advances in occupational health practice will
also be presented. Topics ofthe congress include the influence on health
and well-being of chemical and physical factors, atthe work site, as well
as the impact of ergonomics, psychosocial factors, work organization
and new technology. visitors to earlier ICOH congress will recognize the
general structure of ICOH'96.
Courses
Courses on "Continuous Quality Improvement in Occupational Health
Services" and "Risk Assessment of Carcinogens" will be held in
Stockholm, Sweden, and Helsinki, Finland, in conjunction with the con-
gress. The courses are being organized by the Nordic Institute for
Advanced Training in Occupational Healh (NIVA).
For more information contact:
ICOH Congross
National Institute ofOccupational Healh
S-171 84 Solna
SWEDEN
FAX: (46) 8 82 05 56
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